You are here

As biotech selling spreads, more weakness is seen for US health stocks

The cautious attitude of investors is new for the S&P 500 healthcare sector, which has provided double-digit returns every year since 2011.

New York

AFTER a four-year love affair with healthcare shares, investors are moving on.

Selling has spread from biotechs - shaken on Sept 21 when Hillary Clinton first tweeted concerns about drug prices - to other areas of the healthcare sector. Investors have been dumping shares